BrainScope

We find ourselves at a critical time in Alzheimer’s drug development, where new treatments offer hope for improved quality of life but also carry potential risks. As we've heard recently, these drugs, while promising, can lead to small brain bleeds (ARIAs) that may have serious or even fatal consequences, which can limit their broader use. BrainScope may be able to help. Our FDA-cleared biomarker using AI applied?to EEG identifies the smallest amount of blood that can be reliably seen on a CT scan with 99% sensitivity. We've proven?this with BrainScope's?emergency department customers, which have avoided roughly 50% of CTs for head injury patients, and we've demonstrated that the test can work in stroke patients. So can we do the same for ARIAs and offer a more accessible test than CTs or MRIs? We believe we can. With the?Alzheimer's Drug Discovery Foundation's support, BrainScope has developed a proof of concept biomarker to predict who will develop Alzheimer's. ARIA is next on our roadmap and BrainScope is quickly pursuing developing these diagnostics. We can't think of a better opportunity to make a difference. To learn more, visit https://lnkd.in/gp_iGjNH. Laurie Silver Leslie S Prichep, PhD #BrainScope #Alzheimers #brainbleed #AI #concussion #biomarker https://lnkd.in/gputKzQg

BrainScope has completed the proof-of-concept phase for an AI derived novel EEG-based biomarker that can predict the onset of Alzheimer’s disease in its earliest stages. Supported by the Alzheimer's Drug Discovery Foundation, this breakthrough uses brain activity data to identify cognitive decline before traditional methods can detect the disease. These early insights could transform Alzheimer’s care by enabling timely interventions, offering hope to millions affected. Learn more about how BrainScope is advancing the future of brain health diagnostics: https://bit.ly/4f4eKrx #BrainHealth #AlzheimersAwareness #Innovation

Recent NFL news on concussions and Parkinson’s disease has brought renewed focus on the long-term consequences of repeated head impacts in football. BrainScope’s published research demonstrated that repetitive head trauma is reflected in changes in brain electrical activity often linked to neurodegenerative diseases. This insight is crucial for advancing brain health diagnostics and athlete safety. Read more here: https://lnkd.in/gukqqTE6 #NeuroHealth #ConcussionAwareness #BrainScope #ParkinsonsResearch

BrainScope is having an incredible time at #ACEP2024! We're grateful for the interest and connections from Emergency Physicians worldwide in our technology. Please stop by Booth 1826 between today and tomorrow to learn how BrainScope can support reducing length of stay, diverting unnecessary head CTs, and providing an objective concussion assessment! Laurie Silver Chris Randby Jeff Barish Joe Stauffer

Are you attending #ACEP24? BrainScope will be there! Stop by booth 1826 to learn about how our breakthrough technology can improve the current care pathway for mild head injured patients.

We are excited to announce that BrainScope has been named MedTech Outlook’s Brain Diagnostics Device Company of the Year for 2024! ?? This award recognizes our groundbreaking work in neurodiagnostics, including our development of machine learning and EEG-based biomarkers for point-of-care assessments. We’re also thrilled to be featured in a two-page article, showcasing how our FDA-cleared biomarkers are revolutionizing brain health diagnostics, from brain injuries to Alzheimer’s and stroke. BrainScope is at the forefront of revolutionizing brain health, aiming to improve patient care worldwide. Read more here: https://bit.ly/4dMZ6QT #Innovation #BrainHealth #MedTechOutlook #BrainScope #Alzheimers #Parkinsons

There is an urgent need for quantitative markers that reflect brain dysfunction for improved brain health assessment and monitoring of drug side effects. This presents quite an opportunity for BrainScope‘s deep expertise using brain electrical activity (EEG) paired with advanced AI for development of objective neuro-biomarkers. EEG-based biomarkers have many benefits over traditional markers used in healthcare and pharma today – they are non-invasive, rapid, inexpensive, accessible, and can pick up abnormalities even when no physical symptoms are present. We’re honored to have been invited to attend Longwood Healthcare Leader’s Spring MIT, a networking and brainstorming forum focused on further cultivating biomedical innovation and the advancement of medicines. Having validated outcomes of our three FDA-cleared, EEG-based biomarkers for brain bleed and concussion, we’re excited about the opportunity to meet with pharmaceutical and biotech industry leaders and discuss how we can leverage our deep learning neurotechnology platform across other CNS indications such as Alzheimer’s and Parkinson’s. #BrainScope #brainhealth #Alzheimer’s #Parkinson’s #ARIA

BrainScope has been busy this week talking to brain trauma and concussion thought leaders from around the world. We are grateful for the opportunity to make a real difference in the field.

BrainScope was honored to present at the @USAMRDC / @BARDA Neurotrauma State of Technology conference last week. We have demonstrated the utility of our 3 AI-based biomarkers for brain bleed and concussion in the toughest market (hospital EDs) with outstanding results. Other than CTs there are no objective markers for head injury in use, and CTs can’t pick up concussion (only brain bleeds). It’s time to make BrainScope’s much needed TBI assessment technology available to our service members, veterans, athletes and families. #tbi #traumaticbraininjury #braininjury #headinjury?#braintrauma #concussion #usamrdc #barda #mtec?#dod #wbh #medicalinnovations